Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV.

J Clin Oncol. 2001 Apr 15;19(8):2293-301.

PMID:
11304783
2.

[Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia].

Ma XL, Zhu P, Wu MY, Li ZG, Hu YM.

Zhonghua Er Ke Za Zhi. 2003 Dec;41(12):929-33. Chinese.

PMID:
14723818
3.

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.

Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE.

Ann Intern Med. 1997 Apr 15;126(8):608-14.

PMID:
9103127
4.

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.

J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8.

5.

Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.

Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, Brodkiewicz A, Adrianowska N, Mlynarski W, Januszkiewicz D, Drozdzik M.

Pediatr Blood Cancer. 2011 Oct;57(4):578-82. doi: 10.1002/pbc.23013.

PMID:
21319286
6.

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team..

Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002.

PMID:
26072396
8.

Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.

Cao Q, Zhu Q, Shang Y, Gao M, Si J.

Digestion. 2009;79(1):58-63. doi: 10.1159/000205268.

PMID:
19252404
9.

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium..

Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Erratum in: Clin Pharmacol Ther. 2011 Dec;90(6):894.

10.

Implementation of TPMT testing.

Lennard L.

Br J Clin Pharmacol. 2014 Apr;77(4):704-14. doi: 10.1111/bcp.12226.

11.

Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.

Chrzanowska M, Kuehn M, Januszkiewicz-Lewandowska D, Kurzawski M, Droździk M.

Acta Pol Pharm. 2012 May-Jun;69(3):405-10.

12.

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?

Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H.

Ther Drug Monit. 2012 Dec;34(6):695-701. doi: 10.1097/FTD.0b013e3182731925.

PMID:
23149442
14.

[Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].

Gu LJ, Ye QD, Liang AB, Zhao JC, Xue HL, Tang YN, Chen J, Ye YC.

Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):18-21. Chinese.

PMID:
12679004
15.

The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.

Kurzawski M, Dziewanowski K, Gawrońska-Szklarz B, Domański L, Droździk M.

Ther Drug Monit. 2005 Aug;27(4):435-41.

PMID:
16044099
16.

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.

McLeod HL, Krynetski EY, Relling MV, Evans WE.

Leukemia. 2000 Apr;14(4):567-72. Review.

PMID:
10764140
17.

Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.

Dervieux T, Médard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, Suciu S, Vilmer E, Jacqz-Aigrain E.

Leukemia. 2001 Nov;15(11):1706-12.

PMID:
11681411
18.

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.

Lennard L, Cartwright CS, Wade R, Richards SM, Vora A.

Br J Clin Pharmacol. 2013 Jul;76(1):125-36. doi: 10.1111/bcp.12066.

19.

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, Pousette A, Almer S.

Gut. 2006 Oct;55(10):1423-31.

20.

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.

Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M.

JAMA. 2005 Mar 23;293(12):1485-9.

PMID:
15784872
Items per page

Supplemental Content

Support Center